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Abstract 
Ewing sarcoma is a bone or soft tissue sarcoma most 
commonly diagnosed in adolescents and young 
adults. It is one of the pediatric small, round, blue 
cell tumors and a fusion gene-driven cancer. 
Keywords 
Ewing sarcoma; EWS; EWSR1; FLI1; 




Previous nomenclature: peripheral primitive 
neuroectodermal tumor, Askin's tumor. As of WHO 
2013, these histologic classifications are no longer 
used and these entities are now all referred to as 
Ewing tumors.  
Additionally, there is now an entity of tumors 
deemed "Ewing-like" sarcomas (defined by fusion 
type, see separate entry on Ewing-like sarcomas). 
Note 
Ewing sarcoma is defined by the presence of a fusion 
gene, most commonly EWSR1/FLI1. 
Phylum 
Soft Tissues: Ewing sarcoma 
Classification 
Ewing sarcoma is a tumor of the bone (most 
commonly) or soft tissue and is defined by the 
presence of the fusion gene EWSR1/FLI1 or other 
less common FET/ETS family fusions. 
Clinics and pathology 
Figure 1. Gross dissection map of a treated, resected 
Ewing sarcoma of the femur. Image courtesy of 
Sarangarajan Ranganathan. 
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Phenotype / cell stem origin 
Thought to be derived from a neural crest or 
mesenchymal cell of origin, although the exact cell 
of origin is still a source of debate. 
Etiology 
Ewing tumors arise most commonly from a 
translocation of chromosomes 11 and 22, resulting in 
the generation of the fusion gene EWSR1/FLI1. 
Recent evidence has demonstrated that ~40% of 
Ewing tumors FET/ETS fusions arise from 
chromoplexy. 
Epidemiology 
Ewing sarcoma is a rare subtype of sarcoma. It is the 
second most common primary bone sarcoma in 
pediatric patients and can also occur in the soft 
tissue.  
In the United States, there are 200-250 newly 
diagnosed cases annually. Ewing sarcoma most 
commonly occurs in the AYA (adolescent and young 
adult) patient population, with a peak incidence at 15 
years of age. This tumor can also less commonly 
occur in older adults, with a second smaller peek in 
incidence in patients older than 35 years. There are 
no known environmental exposures known to cause 
Ewing sarcoma. 
Clinics 
Ewing sarcoma can arise in the bone or soft tissue. 
Bone lesions are the most common and occur most 
often in the pelvis or femur. Common locations for 
soft tissue Ewing sarcoma include the buttock, thigh 
and chest wall. Many other bone and soft tissue 
primary locations for Ewing tumors have been 
reported but are less common.  
70-75% of Ewing tumors present as a single, 
localized mass. The remaining ~25% of patients 
present with upfront metastatic disease in the lung or 
bone/bone marrow, as noted on imaging (PET and 
CT scans) and bilateral bone marrow biopsies 
obtained for disease staging. 
Pathology 
Uniform sheets of small, round blue cells, often 
(95%) CD99+ and (100%) Tdt- by 
immunohistochemistry staining. EWSR1 break-
apart FISH probes are commonly used diagnostically 
to detect the presence of the EWS-containing fusion 
(most commonly EWSR1/FLI1). FISH probes are 
not as reliable for detecting EWSR1/ERG or non-
EWSR1 FET/ETS fusions. Tumor sequencing is 
thus also used to more precisely define the fusion 
present in FISH "negative" cases.  
 
Figure 2. A small isolated focus of Ewing tumor cells in the bone marrow. Image courtesy of Sarangarajan Ranganathan 
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Figure 3. H&E section showing sheets of a small blue cell tumor with closely packed cells with indistinct cell borders and 
inconspicuous nucleoli. Note the cytoplasmic clearing. Thin fibrovascular septa are seen in between. (H&E x 200) 
 
 
Figure 4. Higher magnification showing the individual tumor cells that are monomorphic and in sheets with no nucleoli and 
frequent mitoses. Note occasional cells with cytoplasmic eosinophilic staining. A break-apart FISH probe showed EWR1 
rearrangement. (HE x 400) Image courtesy of Sarangarajan Ranganathan 
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Figure 6. A synaptophysin stain showing scattered brown staining in cytoplasm of the tumor cells (Synaptophysin x 400). Image 
courtesy of Sarangarajan Ranganathan 
 
Genes 
Additionally, mutations in the following genes have 
been described in subsets of Ewing tumors: STAG2, 
TP53, EZH2, and deletions inCDKN2A. 
Treatment 
Localized Ewing sarcoma is currently treated with 
alternating, compressed cycles of multi-agent 
chemotherapy, such as VDC/IE (vincristine, 
doxorubicin, cyclophosphamide/ifosfamide, 
etoposide). Ewing tumors are sensitive to radiation 
and local control is achieved by surgery and/or 
radiation therapy.  
Ongoing clinical trials aim to improve the outcomes 
for patients with upfront metastatic and relapsed 
Ewing sarcoma. These trials include international 
efforts to determine the most effective chemotherapy 
backbone for patients with relapsed  
Ewing sarcoma.  
Novel single agents include those attempting to 
target the EWSR1/FLI1 fusion itself. 
Prognosis 
Current survival estimates for patients with primary, 
localized Ewing sarcoma is ~70%. Survival for 
patients with upfront metastatic or relapsed Ewing 
sarcoma is only 10-30%. 
Genetics 
Germline Mutations  
~13% of patients with Ewing sarcoma have been 
found to have germline mutations. These germline 
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mutations are enriched in genes associated with 
DNA damage repair.  
The pathogenicity of such mutations remains a 
subject of ongoing investigation 
Cytogenetics 
Figure 7. t(11;22)(q24;q12) in Ewing sarcoma, G- banding - 
top: courtesy Jean Luc Lai (with trisomy 8 on the right); - 
bottom: courtesy G. Reza Hafez, Eric B.Johnson, and Sara 
Morrison-Delap, UW Cytogenetic Services 
Cytogenetics Morphological 
About 85% of Ewing tumors show a 
t(11;22)(q24;q12); the translocation results in the 
fusion of the EWSR1 gene with the transcription 
factor gene FLI1, leading to a hybrid transcript and 
an oncogenic chimeric protein. Other more rare 
FET-ETS family member fusions have been 
described, such as: t(21;22)(q12;q12) and 
t(7;22)(p22;q12), leading to the fusions 
EWSR1/ERG and EWSR1/ETV1, respectively. 
 
Figure 8. Schematic of the t(11;22)(q24;q12) EWSR1/FLI1 
translocation demonstrating the 5' EWSR1 activation 
domain and the 3' FLI1 ETS DNA binding domain joined by 
a variable length linker region (denoted by the orange bar). 
Additional anomalies 
Additional anomalies in Ewing's tumors mainly 
consist in chromosome gains: +8 (45% of the cases) 
and, with a much lower frequency, trisomies 2, 5, 7, 
9, 12 (between 10 and 15% of the cases); trisomy 1q, 
through unbalanced t(1q;16q), is observed in about 
25% of the cases 
Genes involved and 
proteins 
The following genes have been identified as 
involved FET or ETS family members comprising 
various FET-ETS fusions: EWSR1, FLI1, ERG, 
ETV1, ETV4, FEV, FUS 




Contains both a transcriptional activation domain 
and an RNA-binding domain. 




Member of the ETS family of transcription factors. 
ERG (v-ets erythroblastosis virus E26 
oncogene like (avian)) 
Location 21q22.2 
Protein 
Member of the ETS family of transcription factors. 
ETV1 (Ets variant 1) 
Location 7p21.2 
Protein 
Member of the ETS family of transcription factors. 
ETV4 (Ets variant 4) 
Location 17q21.31 
Protein 
ETV4 serves as a transcriptional activator. 
FEV (fifth ewing variant) 
Location 2q35 
Protein 
Member of the ETS family of transcription factors. 
FUS (fused in sarcoma) 
Location 16p11.2 
Protein 
The FUS protein binds to DNA and participates in 
transcription. 




The 5' portion of FET family members are fused to 
the 3' portion of ETS family members to generate a 




The resulting fusion protein results in an N-terminal 
FET family member with an activation domain 
bound to the C-terminal portion of an ETS family 
protein with DNA binding capabilities.  
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EWSR1/FLI1 t(11;22)  
EWSR1/ERG t(21;22)  
EWSR1/ETV1 t(7;22)  
EWSR1/ETV4 t(17;22)  
EWSR1/FEV t(2;22)  
FUSR1/FEV t(2;16)  
FUSR1/ERG t(16;21) 
Oncogenesis 
The resulting fusion oncoprotein participates in 
transcriptional dysregulation both through activating 
and repressing expression of hundreds of genes. 
EWSR1/FLI1 can interact with promoters to 
enhance gene expression by binding to GGAA 
enriched regions. NROB1 is a classic example of a 
protein upregulated in Ewing sarcoma.  
TGFBR2 (TGF-beta receptor II) expression is one 
example of a gene/protein classically repressed by 
EWS-R1/FLI1. 
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